Lexaria Bioscience’s (LEXX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lexaria Bioscience (NASDAQ:LEXX) in a research note released on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Lexaria Bioscience’s Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($8.00) EPS and FY2025 earnings at ($0.31) EPS.

Lexaria Bioscience Trading Down 1.9 %

Shares of LEXX stock opened at $2.09 on Monday. The company has a market capitalization of $33.06 million, a P/E ratio of -4.45 and a beta of 1.02. The business’s 50 day moving average is $2.64 and its two-hundred day moving average is $2.99. Lexaria Bioscience has a twelve month low of $1.20 and a twelve month high of $6.85.

Hedge Funds Weigh In On Lexaria Bioscience

Several institutional investors have recently bought and sold shares of LEXX. Armistice Capital LLC purchased a new stake in shares of Lexaria Bioscience in the second quarter valued at about $2,836,000. Geode Capital Management LLC lifted its position in Lexaria Bioscience by 31.0% in the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after purchasing an additional 35,608 shares during the period. Renaissance Technologies LLC purchased a new stake in Lexaria Bioscience in the 2nd quarter valued at approximately $63,000. HighTower Advisors LLC acquired a new position in Lexaria Bioscience during the 3rd quarter worth approximately $40,000. Finally, XTX Topco Ltd raised its stake in shares of Lexaria Bioscience by 47.8% during the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock worth $57,000 after buying an additional 6,024 shares in the last quarter. 13.06% of the stock is owned by institutional investors and hedge funds.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.